Incretin mimetics, beyond their beneficial effect on glycemic control, also demonstrate other metabolic benefits, with increasingly clear results on liver damage, through the remission of steatohepatitis and liver fibrosis. This evidence concerns the gene GCG and Hepatic fibrosis.